Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Synthesis of isotopically labeled versions of L-MTP-PE (mifamurtide) and MDP.

Li Y, Plesescu M, Prakash SR.

J Labelled Comp Radiopharm. 2013 Jul-Aug;56(9-10):475-9. doi: 10.1002/jlcr.3078. Epub 2013 Jul 9.

PMID:
24285524
2.

Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.

Meyers PA, Chou AJ.

Adv Exp Med Biol. 2014;804:307-21. doi: 10.1007/978-3-319-04843-7_17. Review.

PMID:
24924182
3.
5.

Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Ando K, Mori K, Corradini N, Redini F, Heymann D.

Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129. Review.

6.

[Synthesis of lipophilic and fluorescent derivatives of N-acetylmuramoyl-L-alanyl-D-isoglutamine].

Bogomolov OV, Golovkina IV, Shvets VI, Bovin NV.

Bioorg Khim. 1993 Feb;19(2):190-6. Russian.

PMID:
8498960
7.

Synthesis and fast-atom-bombardment-mass spectrometry of N-acetylmuramoyl-L-alanyl-D-isoglutamine (MDP).

Phillips LR, Nishimura O, Fraser BA.

Carbohydr Res. 1984 Sep 15;132(2):275-86.

PMID:
6488211
8.

A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.

Venkatakrishnan K, Kramer WG, Synold TW, Goodman DB, Sides E 3rd, Oliva C.

Eur J Clin Pharmacol. 2012 Oct;68(10):1347-55. doi: 10.1007/s00228-012-1262-1. Epub 2012 Mar 30.

PMID:
22460239
11.

Synthesis of fluorescent muramyl dipeptide congeners. 2.

Hiebert CK, Kopp WC, Richerson HB, Barfknecht CF.

J Med Chem. 1988 Oct;31(10):2022-4.

PMID:
3172138
13.

[Synthesis and protective activity of beta-glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine with alkylalicyclic and arylaliphatic aglycons].

Zemliakov AE, Tsikalova VN, Tsikalov VV, Chirva VIa, Mulik EL, Kaliuzhin OV.

Bioorg Khim. 2005 Nov-Dec;31(6):637-44. Russian.

PMID:
16363137
15.

Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.

Asano T, Kleinerman ES.

J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):286-92.

PMID:
8280710
16.

[L-MTP-PE--a potential antineoplastic agent].

Dzierzbicka K, Gozdowska M, Kołodziejczyk AM.

Postepy Hig Med Dosw. 1997;51(2):227-36. Review. Polish.

PMID:
9235567
17.

Activation of macrophage cytostatic and cytotoxic activity in vitro by liposomes containing a new lipophilic muramyl peptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL).

Phillips NC, Moras ML, Chedid L, Petit JF, Tenu JP, Lederer E, Bernard JM, Lefrancier P.

J Biol Response Mod. 1985 Oct;4(5):464-74.

PMID:
3935756
18.

Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.

Kleinerman ES.

Hematol Oncol Clin North Am. 1995 Aug;9(4):927-38. Review.

PMID:
7490249
19.

Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs 1, 2.

Kamisango K, Saiki I, Tanio Y, Kobayashi S, Fukuda T, Sekikawa I, Azuma I, Yamamura Y.

Chem Pharm Bull (Tokyo). 1981 Jun;29(6):1644-54. No abstract available.

PMID:
7296716
20.

Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.

Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N.

Am J Clin Oncol. 1995 Apr;18(2):93-9.

PMID:
7900714

Supplemental Content

Support Center